The global pharmaceutical industry experienced a 7% drop in company filings mentions of orphan designated drugs in Q1 2024 compared with the previous quarter, with the highest share accounted for by BioMarin Pharmaceutical with 50% year-on-year increase, according to GlobalData’s analysis of over 199 pharmaceutical company filings. GlobalData’s Pharma: Filings Trends & Signals Q1 2024 report delves into earnings call transcripts and quarterly reports within the pharmaceuticals industry, extracting trends, signals, and comparative data to help businesses assess their performance, identify competitive intelligence, evaluate risks, and gain a comprehensive understanding of key industry events. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Pharma: Filings Trends & Signals Q1 2024

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

Notably, orphan designated drugs was one of the most frequently referenced themes in Q1 2024, ranking highest in terms of mentions, ahead of robotics and digital banking, according to GlobalData.

Of the top leading companies in the pharmaceutical industry, BioMarin Pharmaceutical had the greatest increase in references for orphan designated drugs in Q1 2024, compared with the previous quarter. GlobalData identified three orphan designated drugs-related sentences in the company's filings - 0.2% of all sentences - and an increase of 50% in Q1 2024 compared with Q1 2023. Alnylam Pharmaceuticals’s mentions of orphan designated drugs to 2 and Legend Biotech’s by 50% to 1.

GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for orphan designated drugs in Q1 2024 was 143.

For further understanding of GlobalData's Pharma: Filings Trends & Signals Q1 2024, buy the report here.

This content was updated on 24 April 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Company Filings Analytics uses machine learning to uncover key insights and track sentiment across millions of regulatory filings and other corporate disclosures for thousands of companies across the world’s largest industries.